In vivo Evaluation of a Newly Synthesized Acetylcholinesterase Inhibitor in a Transgenic Drosophila Model of Alzheimer's Disease

• Published in: Frontiers in neuroscience 2021-06, Vol.15, p.691222-691222
• Main Authors: Uras, Giuseppe, Manca, Alessia, Zhang, Pengfei, Markus, Zsuzsa, Mack, Natalie, Allen, Stephanie, Bo, Marco, Xu, Shengtao, Xu, Jinyi, Georgiou, Marios, Zhu, Zheying
• Format: Article
• Language: English
• Subjects: Acetylcholinesterase; acetylcholinesterase inhibitors; Alzheimer's disease; Amino acids; amyloid aggregation 3; Animal cognition; Aβ42; Clinical trials; Confocal microscopy; Donepezil; Drosophila melanogaster; Enzymes; FDA approval; Gene expression; Insects; Invertebrates; Life span; Medical treatment; Mutation; Neurodegeneration; Neurodegenerative diseases; Neuroscience; Pathogenesis; Patients; Peptides; Proteins; Senile plaques
• ISSN: 1662-4548; 1662-453X; 1662-453X
• DOI: 10.3389/fnins.2021.691222

Alzheimer's disease is a neurodegenerative disease characterized by disrupted memory, learning functions, reduced life expectancy, and locomotor dysfunction, as a result of the accumulation and aggregation of amyloid peptides that cause neuronal damage in neuronal circuits. In the current study, we exploited a transgenic line, expressing amyloid-β peptides to investigate the efficacy of a newly synthesized acetylcholinesterase inhibitor, named XJP-1, as a potential AD therapy. Behavioral assays and confocal microscopy were used to characterize the drug effect on AD symptomatology and amyloid peptide deposition. The symptomatology induced in this particular transgenic model recapitulates the scenario observed in human AD patients, showing a shortened lifespan and reduced locomotor functions, along with a significant accumulation of amyloid plaques in the brain. XJP-1 treatment resulted in a significant improvement of AD symptoms and a reduction of amyloid plaques by diminishing the amyloid aggregation rate. In comparison with clinically effective AD drugs, our results demonstrated that XJP-1 has similar effects on AD symptomatology, but at 10 times lower drug concentration than donepezil. It also showed an earlier beneficial effect on the reduction of amyloid plaques at 10 days after drug treatment, as observed for donepezil at 20 days, while the other drugs tested have no such effect. As a novel and potent AChE inhibitor, our study demonstrates that inhibition of the enzyme AChE by XJP-1 treatment improves the amyloid-induced symptomatology in , by reducing the number of amyloid plaques within the fruit fly CNS. Thus, compound XJP-1 has the therapeutic potential to be further investigated for the treatment of AD.